Current Report Filing (8-k)
November 07 2016 - 8:35AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 7, 2016
RITTER
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-37428
|
|
26-3474527
|
(State
or other
jurisdiction of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer
Identification No.)
|
1880
Century Park East, Suite 1000
|
|
|
Los
Angeles, California
|
|
90067
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
(310) 203-1000
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
2.02. Results of Operation and Financial Condition
On
November 7, 2016, Ritter Pharmaceuticals, Inc. (the “Company”), issued a press release announcing the financial results
for the three-month period ending September 30, 2016, entitled “Ritter Pharmaceuticals Reports Third Quarter 2016 Financial
Results and Provides Business Update” (the “Press Release”). A copy of the Press Release is furnished as Exhibit
99.1 hereto and is incorporated herein by reference.
The
information contained in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed filed for the purposes of
Section 18 of the United State Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of Section 18.
Furthermore, the information shall not be deemed incorporated by reference into any registration statement or any other filing
under the United States Securities Act of 1933, as amended, except as shall be expressly set forth by specific references in such
filings.
Item
9.01. Financial Statements and Exhibits
(d) Exhibits
Exhibit
No.
|
|
Description
|
|
|
|
99.1
|
|
Press
Release dated November 7, 2016, entitled “Ritter Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides
Business Update”
|
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
RITTER PHARMACEUTICALS, INC.
|
|
|
|
|
By:
|
/s/
Michael D. Step
|
|
Name:
|
Michael
D. Step
|
|
Title:
|
Chief
Executive Officer
|
Date: November
7, 2016
Exhibit
Index
Exhibit
No.
|
|
Description
|
|
|
|
99.1
|
|
Press
Release dated November 7, 2016, entitled “Ritter Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides
Business Update”
|
Ritter Pharmaceuticals (NASDAQ:RTTR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ritter Pharmaceuticals (NASDAQ:RTTR)
Historical Stock Chart
From Sep 2023 to Sep 2024